he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
拍照信源地址
上一页:幼儿癫痫病的20世纪症状是什么
- 2022-05-05麻风病的症状有哪些 应该这样治疗麻风病
- 2022-04-26一文掌握中风用药宝典
- 2022-04-252013年国际性抗癫痫联合会抗癫痫药使用指南
- 2022-04-21痉挛患儿死亡简析
- 2022-04-13【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 2022-04-12FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 副教授赵倩华谈到了认知障碍的早期诊断策略
- 癫痫患者手术评估新型工具
- 由于医生的原因,物「沉默」而且很难进入处方
- 癫痫猝死:凶手是谁?
- 中华医学会系列精选指南|急性腹痛、淋巴瘤、银屑病的诊断和治疗
- 广西百色破获药案:涉及74家药店,3000多盒
- 预测癫痫患者再入院风险
- 导致皮肤问题的原因有六个
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- 2015第31届国际癫痫大会(IEC)
- 油炸刀鱼 酥脆的美味食物
- 2015 神经系统疾病诊疗进展
- 血清钙水平可预测甲氨蝶呤治疗银屑病的效果
- FDA警告怀孕期间使用丙戊酸钠药物
- 世界癫痫日 | 科学防治 标准诊疗 告别癫痫
- 综述:癫痫持续状态诊治最新进展
- 诺华Cosentyx欧盟批准治疗中重度斑块状银屑病
- 癫痫症状 如何护理癫痫患者?
- 不同年龄段癫痫的病因是什么?
- FDA批准塞尔基因Otezla治疗银屑病性关节炎
- 中医对白癜风的病因
- 癫痫治疗障碍仍难以克服
- 为什么女教师成为男性的首选目标(3)
- 孩子脸上有白斑,肚子里有蛔虫?医生:不是蛔虫斑,可能是癌症
- 这些食物其实并不安全109
- 试验性依那西普生物类似物 CHS-0214 3 期研究的主要终点
- 最新用药癫痫病方法有什么
- 为什么在月经期间不易犯癫痫病?
- 癫痫病症状 怎样护理人员癫痫病人
- Medpage Today:不同类别抗癫痫药物的联用越来越有利
- 天使科普:罕见的癫痫治疗误区都有哪些?
- Radiology:利用MR指纹识别评价内侧额叶癫痫病灶的价值
- 帕金森氏症的治疗 治疗帕金森氏症的偏方大全
- 欧洲委员会扩展批准优时比抗癫痫药物 Vimpat 用于儿童患者
- 抗病毒癫痫将有新治疗手段
- 怎样病患癫痫病病患方法
- 诊治良性癫痫病有什么症状
- 《英国医学杂志》发表文章同意将烟草依赖定义为致死性慢病